Related Experiment Video
Updated: Jul 16, 2026
Embryo Transfer Surgery via Laparotomy in Gilts
Published on: October 18, 2024
Intravaginal gemeprost and second-trimester pregnancy termination in the scarred uterus
E Marinoni1, M Santoro, M P Vitagliano
1Laboratory of Perinatal Medicine and Molecular Biology, Department of Gynecology, Perinatology and Child Health, University La Sapienza, Rome, Italy. emanuelamarinoni@hotmail.com <emanuelamarinoni@hotmail.com>
Objective:
To investigate the effectiveness and complication rate of intravaginal gemeprost, a prostaglandin E(1) analogue, for second-trimester pregnancy termination in women with a scarred uterus.
Methods:
Of 439 women undergoing induced abortion between the 13th and the 23rd week of pregnancy, 67 had a scarred uterus because of 1 or more cesarean sections or myomectomy. All women received a 1 mg dose of gemeprost intravaginally every 3 h, up to 5 times over 24 h. Those who did not respond received further cycles of gemeprost treatment.
Results:
The rate of successful abortions among women with uterine scars was not different from that observed in the nulliparous controls, but previously vaginal delivery was associated with a shorter induction to abortion interval. The rate of severe complications did not differ between the groups, and was about 1%.
Conclusion:
The rate of complications following intravaginal administration of a PGE(1) analogue for second-trimester pregnancy termination was similar in women with a scarred or unscarred uterus.
